资源描述：
《免疫性血小板减少症患者外周血细胞因子谱检测及临床意义》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、结论：TPO、IL-lkIL-17>TGF-P这四种细胞因子在ITP的发病机制中起到重要作用，其检测对ITP有一定的辅助诊断、评估预后及指导治疗的意义。关键词：免疫性血小板减少症T淋巴细胞细胞因子中图分类号：R558文献标识码：AAbstractObjective：Exploringthechangesandclinicalsignificanceofcytokines(IFN-y,IL・2,IL-12,IL-4,IL-6,IL-10,TNF-a,IL-27,IL-17,IL-11,TPO,TG
2、F-p)inthesamebatchITPpatients.Methods：1.Collectingtheplasmaof20ITPpatientsbeforeandaftertreatmentandother20healthycontrols(controlgroup).ThendetectingtheplasmalevelsofdifferentcytokineswithELISA.2.Detectingthedifferentgroups5cytokines'mRNAlevelinperi
3、pheralmononuclearcellwithReal-timeRT-PCR.Statisticmethod:DatawereanalysedbySPSS17.0statisticalsoftware・Normaldistributiondatawerepresentedwithmean土standarddeviation(x±s)andthecomparisonbetweenbeforetreatmentandtreatmentgroupwereconductedwiththepaired
4、ttest,whilethedatabetweenbeforetreatmentandcontrolgroupwereanalysedwithindependentsamplettest.Skeweddistributionmeasurementdatausingranksumtest,testleveltakea=0.05.Results：1.Incomparedtothecontentsofdifferentcytokinesofdifferentgroup,therewerenostati
5、sticdifferencesinIFN-y,TNF-a,IL-2,IL-12,IL-4,IL-6,IL-10,IL-27betweenbeforetreatmentandcontrolgroup・Furthermore,nostatisticdifferenceswerefoundincontentsofIFN-y,TNF-a,IL-2,IL-12,IL-4,IL-6,IL-10,IL-27betweenbeforetreatmentandtreatmentgroup.BesidesIL-12
6、p40mRNAexpressionlevelofbeforetrcatmcnt(4.97±3.62)weredramaticallyhigherthancontrolgroup(2.33±2.15),amongthesethreegroupsofperipheralmononuclearcells,mRNAexpressionlevelsofIFN-y,TNF-a?IL-2,IL-12p40,IL-4,IL-6?IL-10andIL-27hadnostatisticdifferences.2.w
7、hiletheplasmalevelsofIL-17,TPO,IL-11beforetreatment(12.29±8.63pg/ml,133.21±61.34pg/ml,564.2l±893.77pg/ml)weremuchhigherthancontrolgroup(6.89±4.70pg/ml,46.08±41.71pg/ml,52.98±1.93pg/ml)(P<0.01).IncomparedtotheplasmalevelofIL-11hasnostatisticdifference
8、sbetweenbeforetreatmentandaftergroup.Incontrast,theplasmalevelsofIL-17andTPOweresignificantlydecreaseaftertreatment(8.20±4.43pg/ml,77.07±63.86pg/ml)(P<0.05).3.TheplasmalevelofTGF-pbeforetreatment(55.76±40.49pg/ml)weremuchhigherthancontrolgroup(435.65
